A Fight against COVID-19:Bioperfectus Total Diagnostic Solution for COVID-19

Company news
2021-08-05

On 3rd September 2022, there have been nearly 605,912,418 confirmed cases of COVID-19 globally, reported from WHO. On 11th March 2020. Variants of concern have appeared at regular intervals—Alpha, Beta, Gamma, Delta, and now Omicron. Omicron variant, first identified in Botswana in November 2021, is rapidly becoming the dominant circulating variant.

 

We, Bioperfectus, as one of the leading professional manufacturers of molecular diagnostic solution, provides the total solution in COVID-19 diagnosis including nucleic acid purification, SARS-CoV-2 Real-time PCR & rapid test, which will help professionals and untrained users to detect COVID-19.

 

 

 

  • COVID-19 Coronavirus Real Time PCR Kits

COVID-19 Coronavirus Real Time PCR Kit was the first group of kits granted with WHO-EUL, FDA-EUA and CE at the same time. Excellent performance with Clinical Sensitivity 100% and Clinical Specificity 99.8%. In this week, Bioperfectus has 100% passed the EQA from National Center for Clinical Laboratories of China for SARS-CoV-2 Variants. At the same time, we also provide COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit which receives CE mark.

 

  • Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kits

Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit has been included in EU Common List and passed PEI evaluation in Germany. Also, asymptomatic cases detectable have been proven by the laboratory with CLIA certificate of registration in the U.S.

 

Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) receives a CE mark, applicable to both asymptomatic and symptomatic individuals. 

 

  • SARS-CoV-2 Variants Real Time PCR Kits

SARS-CoV-2 Variant Omicron Real Time PCR Kit, with the detection of the ORF1ab gene and mutation sites of E484A, N679K, L981F, and H655Y of S gene, this new kit could help to identify the Omicron variant conveniently and effectively.

 

SARS-CoV-2 Variant B.1.617 Real Time PCR Kit identifies Delta Variant (B.1.617.2), B.1.617 Variant, and SARS-COV-2 in one test, but is also equipped with an automated result interpretation add-in, which will help the clinicians to identify mutations and Delta variant immediately after amplification.

 

SARS-CoV-2 Variant Lambda (C.37) Real Time PCR Kit can detect four targets (ORF1a/b, F490S, T76I, and internal control) simultaneously in one tube, support automated result interpretation with STC-96A & 96A Plus.

 

  • COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit

COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit aims to detect and differentiate RNA from SARS-CoV-2 qualitatively, influenza A virus, and/or influenza B virus from upper and lower respiratory tract samples. One-tube test that reports three viruses (influenza A, influenza B, and COVID-19) can enhance testing capacity, especially during the flu season.

 

In the fight against the COVID-19 pandemic, Bioperfectus has been improving infection prevention and control diagnostic solution to protect patients and staff and prevent further spread of COVID-19.

 

We are looking for global distributors, please send an inquiry email to info@bioperfectus.com, media & news release cooperation, please email to marketing_global@bioperfectus.com

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14